The differential expression of Kiss1, MMP9 and angiogenic regulators across the feto-maternal interface of healthy human pregnancies:implications for trophoblast invasion and vessel development

Genes involved in invasion of trophoblast cells and angiogenesis are crucial in determining pregnancy outcome. We therefore studied expression profiles of these genes in both fetal and maternal tissues to enhance our understanding of feto-maternal dialogue. We investigated the expression of genes involved in trophoblast invasion, namely Kiss1, Kiss1 Receptor (Kiss1R) and MMP9 as well as the expression of angiogenic ligands Vascular Endothelial Growth Factor-A ( VEGF-A) and Prokineticin-1 ( PROK1 ) and their respective receptors (VEGFR1, VEGFR2 and PROK1R ) across the feto-maternal interface of healthy human pregnancies. The placenta, placental bed and decidua parietalis were sampled at elective caesarean delivery. Real-time RT-PCR was used to investigate transcription, while immunohistochemistry and western blot analyses were utilized to study protein expression. We found that the expression of Kiss1 (p<0.001), Kiss1R (p<0.05) and MMP9 (p<0.01) were higher in the placenta compared to the placental bed and decidua parietalis. In contrast, the expression of VEGF-A was highest in the placental bed ( p<0.001 ). While VEGFR1 expression was highest in the placenta (p<0.01), the expression of VEGFR2 was highest in the placental bed (p<0.001). Lastly, both PROK1 (p<0.001) and its receptor PROK1R (p<0.001) had highest expression in the placenta. Genes associated with trophoblast invasion were highly expressed in the placenta which could suggest that the influence on invasion capacity may largely be exercised at the fetal level. Furthermore, our findings on angiogenic gene expression profiles suggest that angiogenesis may be regulated by two distinct pathways with the PROK1/PROK1R system specifically mediating angiogenesis in the fetus and VEGFA/VEGFR2 ligand-receptor pair predominantly mediating maternal angiogenesis

IoT and mobile app-based food spoilage alert system

Food is one of the necessities of human life. It is mandatory to maintain a balanced diet with fresh fruits and vegetables to maintain good health conditions. In this fast-forwarded generation, consumers often expect faster delivery of fruits, vegetables, and even food products. For this purpose, the food materials are stored in bulk storage areas. Every type of food requires its environment to stay fresh for a long time. When different types of food materials in enormous amounts are stored in one area, it becomes tougher for the one who manages the storage area to maintain optimum values for all parameters. It also becomes difficult to identify whether the food inside a compartment is fresh or rotten. To help this scenario, this study aims the development an Internet of Things (IoT) system which is capable of monitoring the necessary parameters. This system consists of sensors, a controller, and software. The sensors are directly linked to the food materials that need to be monitored. The nodeMCU module receives and processes the data collected from the sensors. The information gathered is sent to the Blynk mobile application. The collected data is then analyzed or compared to the parameter threshold values

Maternal serum soluble CD30 is increased in normal pregnancy, but decreased in preeclampsia and small for gestational age pregnancies

OBJECTIVE: Women with preeclampsia and those who deliver small for gestational age (SGA) neonates are characterized by intravascular inflammation (T helper 1 (Th1)-biased immune response). There is controversy about the T helper 2 (Th2) response in preeclampsia and SGA. CD30, a member of the tumor necrosis factor receptor superfamily, is preferentially expressed in vitro and in vivo by activated T cells producing Th2-type cytokines. Its soluble form (sCD30) has been proposed to be an index of Th2 immune response. The objective of this study was to determine whether maternal serum concentration of sCD30 changes with normal pregnancy, as well as in mothers with preeclampsia and those who deliver SGA neonates. METHODS: This cross-sectional study included patients in the following groups: (1) non-pregnant women (N=49); (2) patients with a normal pregnancy (N=89); (3) patients with preeclampsia (N=100); and (4) patients who delivered an SGA neonates (N=78). Maternal serum concentration of sCD30 was measured by a specific and sensitive enzyme-linked immunoassay. Non-parametric tests with post-hoc analysis were used for comparisons. A p value <0.05 was considered statistically significant. RESULTS: (1) The median sCD30 serum concentration of pregnant women was significantly higher than that of non-pregnant women (median: 29.7 U/mL, range: 12.2-313.2 vs. median: 23.2 U/mL, range: 14.6-195.1, respectively; p=0.01); (2) Patients with preeclampsia had a significantly lower median serum concentration of sCD30 than normal pregnant women (median: 24.7 U/mL, range: 7.6-71.2 vs. median: 29.7 U/mL, range: 12.2-313.2, respectively; p<0.05); (3) Mothers with SGA neonates had a lower median concentration of sCD30 than normal pregnant women (median: 23.4 U/mL, range: 7.1-105.3 vs. median: 29.7 U/mL, range: 12.2-313.2, respectively; p<0.05); and (4) There was no significant correlation (r=-0.059, p=0.5) between maternal serum sCD30 concentration and gestational age (19-38 weeks) in normal pregnant women. CONCLUSIONS: (1) Patients with preeclampsia and those who deliver a SGA neonate had a significantly lower serum concentration of sCD30 than normal pregnant women; (2) This finding is consistent with the view that preeclampsia and SGA are associated with a polarized Th1 immune response and, perhaps, a reduced Th2 response